Newron Pharmaceuticals Raises EUR 30 Million
24-Feb-2005
Newron will use the proceeds of the financing primarily to further advance the worldwide Phase III development of Safinamide for Parkinson's disease as well as preparing to move the compound forward in other indications. In addition, the funds will be used to progress the development of the neuropathic pain project currently in phase II and the preclinical stage compounds through clinical trials.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.